com_NN Health_NNP problems_NNS related_VBN to_TO the_DT function_NN Key_NNP product_NN sales_NNS :_: Cardiovascular_NNP With_IN its_PRP$ novel_NN mode_NN of_IN action_NN ,_, Faslodex_NNP 2004_CD 2003_CD Underlying_NNP of_IN the_DT central_JJ nervous_JJ system_NN ,_, including_VBG offers_NNS an_DT effective_JJ ,_, well-tolerated_JJ additional_JJ $_$ m_CD $_$ m_JJ growth_NN %_NN the_DT brain_NN ,_, are_VBP a_DT complex_JJ area_NN of_IN significant_JJ breast_NN cancer_NN therapy_NN ,_, in_IN a_DT convenient_JJ Seloken_NNP 1,387_CD 1,280_CD 6_CD medical_JJ need_NN ._.
Following_VBG EU_NNP Crestor_NNP 908_CD 129_CD n_NN m_NN approval_NN in_IN March_NNP 2004_CD ,_, Faslodex_NNP is_VBZ Atacand_NNP 879_CD 750_CD 10_CD In_IN September_NNP 2004_CD ,_, Seroquel_NNP became_VBD now_RB available_JJ in_IN Europe_NNP as_RB well_RB as_IN the_DT Plendil_NNP 455_CD 540_CD 20_CD the_DT market_NN leading_VBG atypical_JJ anti-psychotic_JJ US_NNP ,_, Brazil_NNP and_CC Argentina_NNP for_IN the_DT Zestril_NNP 440_CD 478_CD 15_CD in_IN the_DT US_NNP in_IN terms_NNS of_IN monthly_JJ new_JJ treatment_NN of_IN advanced_JJ breast_NN cancer_NN Tenormin_NNP 368_CD 342_CD prescriptions_NNS ._.
In_IN Europe_NNP ,_, Seroquel_NNP is_VBZ in_IN post-menopausal_JJ women_NNS ._.
Other_JJ 340_CD 391_CD 20_CD growing_VBG two_CD to_TO three_CD times_NNS faster_JJR than_IN the_DT Total_JJ 4,777_CD 3,910_CD 17_CD atypical_JJ market_NN ,_, with_IN excellent_JJ market_NN Sales_NNS of_IN Casodex_NNP and_CC Arimidex_NNP ,_, for_IN treating_VBG share_NN gains_NNS ,_, notably_RB in_IN Italy_NNP and_CC Germany_NNP ._.
prostate_NN and_CC breast_NN cancer_NN respectively_RB ,_, Key_NNP product_NN sales_NNS :_: Gastrointestinal_JJ showed_VBD continued_VBN good_JJ growth_NN ._.
Further_JJ 2004_CD 2003_CD Underlying_JJ $_$ m_CD $_$ m_JJ growth_NN %_NN The_DT launch_NN of_IN Seroquel_NNP in_IN the_DT US_NNP and_CC large-scale_JJ clinical_JJ study_NN data_NNS presented_VBN in_IN Nexium_NNP 3,883_CD 3,302_CD 15_CD Europe_NNP for_IN the_DT treatment_NN of_IN bipolar_NN mania_NN December_NNP 2004_CD showed_VBD that_IN Arimidex_NNP is_VBZ Losec_NNP Prilosec_NNP 1,947_CD 2,565_CD 30_CD which_WDT affects_VBZ over_IN 17_CD million_CD people_NNS in_IN the_DT significantly_RB more_RBR effective_JJ than_IN tamoxifen_JJ Other_JJ 88_CD 76_CD 9_CD major_JJ markets_NNS has_VBZ been_VBN very_RB successful_JJ ,_, in_IN prolonging_VBG disease-free_JJ survival_NN ._.
The_DT Total_JJ 5,918_CD 5,943_CD 4_CD with_IN strong_JJ market_NN share_NN growth_NN ._.
same_JJ study_NN also_RB showed_VBD that_IN women_NNS switching_VBG from_IN tamoxifen_NN to_TO Arimidex_NNP Key_NNP product_NN sales_NNS :_: Infection_NNP Following_VBG successful_JJ launches_NNS in_IN the_DT US_NNP suffer_VBP fewer_JJR recurrences_NNS of_IN their_PRP$ early_JJ 2004_CD 2003_CD Underlying_JJ and_CC Europe_NNP of_IN Zomig_NNP Nasal_NNP Spray_NNP ,_, a_DT new_JJ breast_NN cancer_NN than_IN those_DT who_WP stay_VBP on_IN $_$ m_CD $_$ m_JJ growth_NN %_NN formulation_NN of_IN our_PRP$ Zomig_NNP migraine_NN therapy_NN tamoxifen_NN through_IN the_DT standard_JJ five-year_JJ Merrem_NNP 423_CD 346_CD 15_CD in_IN a_DT convenient_JJ device_NN that_WDT delivers_VBZ fast_RB course_NN of_IN treatment_NN ._.
Other_JJ 116_CD 130_CD 16_CD pain_NN relief_NN ,_, we_PRP anticipate_VBP launch_NN in_IN Japan_NNP Total_NNP 539_CD 476_CD 7_CD in_IN 2005_CD ._.
Respiratory_NNP and_CC Inflammation_NNP Already_RB a_DT leader_NN in_IN the_DT treatment_NN of_IN asthma_NN ,_, Key_NNP product_NN sales_NNS :_: Neuroscience_NNP Our_PRP$ leading_VBG range_NN of_IN anaesthetics_NNS continued_VBD we_PRP plan_VBP to_TO expand_VB our_PRP$ range_NN through_IN the_DT 2004_CD 2003_CD Underlying_JJ $_$ m_CD $_$ m_JJ growth_NN %_NN to_TO perform_VB well_RB ._.
Anaesthesia_NNP sales_NNS introduction_NN of_IN new_JJ uses_NNS for_IN our_PRP$ key_JJ Seroquel_NNP 2,027_CD 1,487_CD 33_CD exceeded_VBD $_$ 1_CD billion_CD in_IN 2004_CD including_VBG $_$ 500_CD products_NNS and_CC new_JJ treatments_NNS in_IN other_JJ Diprivan_NNP 500_CD 458_CD 5_CD million_CD of_IN Diprivan_JJ sales_NNS ._.
areas_NNS of_IN inflammatory_JJ disease_NN ,_, such_JJ as_IN Zomig_NNP 356_CD 349_CD 3_CD chronic_NN obstructive_JJ pulmonary_JJ disease_NN Local_JJ anaesthetics_NNS 542_CD 466_CD 8_CD Oncology_NNP COPD_NNP and_CC rheumatoid_JJ arthritis_NN ._.
Other_JJ 71_CD 73_CD 10_CD We_PRP aim_VBP to_TO maintain_VB our_PRP$ position_NN as_IN a_DT Total_JJ 3,496_CD 2,833_CD 19_CD world_NN leader_NN in_IN cancer_NN treatment_NN through_IN The_DT World_NNP Health_NNP Organization_NNP estimates_VBZ further_JJ launches_NNS for_IN our_PRP$ new_JJ products_NNS ,_, that_IN 100_CD million_CD people_NNS worldwide_JJ suffer_VBP Key_NNP product_NN sales_NNS :_: Oncology_NNP the_DT successful_JJ introduction_NN of_IN novel_NN from_IN asthma_NN and_CC that_IN COPD_NNP is_VBZ the_DT fourth_JJ 2004_CD 2003_CD Underlying_JJ approaches_NNS currently_RB in_IN the_DT pipeline_NN and_CC greatest_JJS cause_NN of_IN death_NN worldwide_NN ._.
$_$ m_CD $_$ m_JJ growth_NN %_NN the_DT continued_JJ growth_NN of_IN key_JJ products_NNS Casodex_NNP 1,012_CD 854_CD 11_CD in_IN our_PRP$ portfolio_NN ._.
Clinical_JJ data_NNS confirm_VBP the_DT efficacy_NN and_CC safety_NN Zoladex_NNP 917_CD 869_CD 1_CD of_IN Symbicort_NNP as_IN an_DT adjustable_JJ maintenance_NN Arimidex_NNP 811_CD 519_CD 48_CD Six_CD million_CD people_NNS die_VBP from_IN cancer_NN every_DT treatment_NN for_IN asthma_NN ,_, providing_VBG superior_JJ Iressa_NNP 389_CD 228_CD 65_CD year_NN representing_VBG 12_CD %_NN of_IN deaths_NNS worldwide_VBP ._.
asthma_NN control_NN compared_VBN to_TO traditional_JJ Nolvadex_NNP 134_CD 178_CD 31_CD Symbicort_NNP fixed_VBN dose_NN treatment_NN ._.
During_IN Faslodex_NNP 99_CD 77_CD 28_CD Iressa_NNP ,_, used_VBN for_IN the_DT treatment_NN of_IN non-small_JJ the_DT year_NN ,_, we_PRP withdrew_VBD our_PRP$ regulatory_JJ Other_JJ 14_CD 18_CD 28_CD cell_NN lung_NN cancer_NN ,_, is_VBZ a_DT highly_RB researched_VBN submission_NN in_IN Europe_NNP for_IN Symbicort_NNP single_JJ Total_JJ 3,376_CD 2,743_CD 16_CD anti-cancer_JJ agent_NN that_WDT acts_VBZ to_TO block_VB signals_NNS inhaler_JJR therapy_NN SiT_NN ._.
We_PRP aim_VBP to_TO submit_VB a_DT for_IN cancer_NN cell_NN growth_NN and_CC survival_NN ._.
regulatory_JJ filing_NN in_IN the_DT second_JJ half_NN of_IN 2005_CD Key_NNP product_NN sales_NNS :_: However_RB ,_, in_IN December_NNP 2004_CD initial_JJ results_NNS for_IN Symbicort_NNP SiT_NNP containing_VBG additional_JJ Respiratory_NNP &_CC Inflammation_NNP from_IN the_DT recent_JJ ISEL_NNP study_NN showed_VBD that_IN data_NNS from_IN further_JJ ongoing_JJ studies_NNS ._.
A_DT 2004_CD 2003_CD Underlying_JJ $_$ m_CD $_$ m_JJ growth_NN %_NN statistically_RB ,_, Iressa_NNP did_VBD not_RB significantly_RB regulatory_JJ application_NN for_IN approval_NN in_IN Pulmicort_NNP 1,050_CD 968_CD 4_CD increase_NN survival_NN of_IN the_DT overall_JJ population_NN ._.
Europe_NNP of_IN Symbicort_NNP pressurized_VBD metered_VBN Symbicort_NNP 797_CD 549_CD 32_CD Data_NNP suggest_VBP survival_NN benefits_NNS in_IN patient_JJ dose_NN inhaler_NN for_IN use_NN in_IN asthma_NN and_CC in_IN Rhinocort_NNP 361_CD 364_CD 3_CD populations_NNS of_IN East_JJ Asian_JJ origin_NN and_CC in_IN COPD_NNP was_VBD made_VBN in_IN July_NNP 2004_CD ._.
Iressa_NNP is_VBZ approved_VBN in_IN 35_CD Oxis_NNP 101_CD 120_CD 24_CD countries_NNS including_VBG the_DT US_NNP and_CC Japan_NNP ._.
In_IN the_DT US_NNP ,_, sales_NNS of_IN Pulmicort_NNP Respules_NNP Other_JJ 158_CD 153_CD 5_CD We_PRP are_VBP now_RB in_IN consultation_NN with_IN regulatory_JJ continue_VBP to_TO grow_VB ,_, further_JJ strengthening_VBG its_PRP$ Total_JJ 2,583_CD 2,261_CD 8_CD authorities_NNS to_TO determine_VB the_DT impact_NN of_IN the_DT position_NN as_IN the_DT inhaled_JJ corticosteroid_NN of_IN ISEL_NNP data_NNS ._.
We_PRP have_VBP withdrawn_VBN the_DT choice_NN for_IN the_DT treatment_NN of_IN children_NNS under_IN n_NN m_NN not_RB meaningful_JJ European_JJ Marketing_NNP Authorisation_NNP five_CD with_IN asthma_NN ._.
Application_NN and_CC voluntarily_RB suspended_VBN promotion_NN of_IN Iressa_NNP in_IN the_DT US_NNP ._.
We_PRP intend_VBP however_RB to_TO continue_VB to_TO make_VB Iressa_NNP available_JJ for_IN patients_NNS whose_WP$ physicians_NNS feel_VBP they_PRP are_VBP benefiting_VBG from_IN the_DT drug_NN ._.
